Our mission is to discover drugs for high unmet medical needs that will improve quality of life for patients with Rare Diseases.
We stand out by our ability to deliver high value products with relatively little cost in a short period of time, due to our model we reduce the risk of drug development.
SOM Biotech has a strong pipeline of products focused on CNS at preclinical and clinical stages.
NEWS & PRESS RELEASES
Executing strategies for maximizing firm value
2018 WAS ANOTHER IMPORTANT YEAR FOR SOM BIOTECH with new rounds of investments, a clinical […]
Season’s greetings from SOM
Each year, the SOM Biotech team celebrates Christmas by dining out and doing some fun activities […]
Early Stage Value Creation Panel Discussion
Farmantra, a Barcelona-based corporate finance advisory for life sciences companies specializing in early stage valuations, […]
SOMCT02 Huntington’s disease trial recruits 50% of patient target
On November 2, 2018, the SOMCT02 clinical trial successfully recruited its 15th patient, marking 50% […]
SOM Biotech at BIO Europe 2018
Europe’s largest annual life science partnering conference was held on November 5-7, 2018 in Copenhagen. BIO Europe […]
SOM Biotech invited to “Preferències” radio show
Each month, “Preferències” director and host Josep Maria Carrasco presents companies of special interest located […]
SOM Biotech joins Euronext TechShare Programme
Euronext, the first and largest pan-European stock exchange in the Eurozone, launched its fourth session of TechShare, the […]
Workshop on Transfer of Scientific Knowledge in Duchenne Muscular Dystrophy
The 3rd Workshop on the Transfer of Scientific Knowledge in Duchenne Muscular Dystrophy was held […]
World Duchenne Awareness Day 2018
September 7 is World Duchenne Awareness Day. In celebration of this awareness-raising event, SOM Biotech […]
SOM Biotech at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology 2018
BIT’s 16th Annual Congress of International Drug Discovery Science and Technology (IDDST 2018) was held on […]